Lithuania Pharmaceuticals & Healthcare Report

Published 02 April 2015

  • 101 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Lithuania Pharmaceuticals & Healthcare Report

BMI View: The deteriorating macro outlook for Russia will impact Lithuania's economy , with negative effects on fiscal planning and therefore the pharmac eutical and healthcare sectors. However, the centre-left government's partial reversal of austerity measures, raising of minimum wages and boosts to unemployment benefits will provide some relief in the short term from external factors.

Headline Expenditure Projections

  • Pharmaceuticals: EUR600mn (USD810mn) in 2014 to EUR630mn(USD691mn) in 2015; +4.4% in local currency terms and -14.3% in US dollar terms.

  • Healthcare: EUR2.40bn (USD3.1bn) in 2014 to EUR2.4bn (USD2.6bn) in 2015; +4.2% in local currency terms and -14.4% in US dollar terms.

Risk/Reward Index

Despite its accession to the EU, Lithuania offers a limited opportunity to drugmakers over the long term. Lithuania has an RRI score of 46.8 out of 100, making it the 17th most attractive pharmaceutical market in Central and Eastern Europe. Lithuania scores below the regional average score of 51.1 in Q215. Lithuania scores (12.4) below the regional average for Industry Rewards (18.6), with the country's limited size and growth prospects holding back its score. Lithuania's overall reward score is below average (31.5), highlighting the limited growth outlook for pharmaceuticals and the small overall size of the Lithuanian market.

Key Trends and Developments

  • In March 2015, the Lithuanian parliament passed on amendment to the Law On Medicines enabling pharmacists to give pharmaceutical advice to patients, reflecting a trend seen in many Western European countries and intended to ease pressure on clinics.

  • In February 2015, the Special Investigation Service opened an investigation into allegations of large scale bribery between drugmaker Valentis and representatives of various medical instutitions, doctors and public officials.

  • The Parliamentary Health Committee discussed in December 2014 how and when Lithuania will implement pharmacies delivering vaccines...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Lithuania Pharmaceutical Sales, Historical Data And Forecasts
15
Healthcare Market Forecast
16
Table: Lithuania Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Lithuania Government Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: Lithuania Private Healthcare Expenditure Trends, Historical Data And Forecasts
18
Prescription Drug Market Forecast
19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2010-2018)
20
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2010-2018)
22
Generic Drug Market Forecast
23
Table: Lithuania Generic Drug Market Indicators, Historical Data And Forecasts
24
OTC Medicine Market Forecast
25
Table: Lithuania Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
26
Pharmaceutical Trade Forecast
27
Table: Lithuania Pharmaceutical Trade Data And Forecasts
28
Table: Lithuania Pharmaceutical Trade Data And Forecasts local currency
28
Key Risks To BMI's Forecast Scenario
29
Macroeconomic Forecasts
30
Economic Analysis
30
Table: Economic Activity (Lithuania 2009-2018)
32
Industry Risk Reward Ratings
33
Central And Eastern Europe Risk/Reward Ratings
33
Lithuania Risk/Reward Ratings
40
Rewards
40
Risks
40
Market Overview
42
Industry Trends And Developments
43
Epidemiology
43
Table: Leading Causes of Death, 2002-2010
44
Communicable Diseases
44
Table: Incidence of HIV & AIDS, 2002-2010
45
Healthcare System
45
Healthcare Provision
46
Table: Inpatient Institutions & Hospital Beds by Sector, 2000-2010
46
Table: Outpatient Facilities by Type, 2003-2010
47
Healthcare Funding
47
Healthcare Insurance
48
Biotechnology
48
Clinical Trials
50
Regulatory Development
51
Regional Harmonisation
52
Pharmaceutical Advertising
53
Intellectual Property Developments
54
Pricing Regime
55
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines
56
Reimbursement Regime
57
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines
58
Reimbursement Developments
58
Competitive Landscape
60
Pharmaceutical Industry
60
Table: Members of the Association of Manufacturers of Drugs (VGA), 2013
60
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)
61
Domestic Industry
61
Recent Company Developments
62
Pharmaceutical Wholesale
63
Pharmaceutical Retail
64
Table: Pharmacies, 2000-2010
65
Company Profile
67
Valentis
67
Sanitas (Valeant)
69
Sicor Biotech (Teva)
72
GlaxoSmithKline
75
Pfizer
77
Novartis
79
Merck & Co
81
Sanofi
83
Demographic Forecast
85
Table: Lithuania's Population By Age Group, 1990-2020 ('000)
86
Table: Lithuania's Population By Age Group, 1990-2020 (% of total)
87
Table: Lithuania's Key Population Ratios, 1990-2020
88
Table: Lithuania's Rural And Urban Population, 1990-2020
88
Glossary
89
Methodology
91
Pharmaceutical Expenditure Forecast Model
91
Healthcare Expenditure Forecast Model
91
Notes On Methodology
92
Risk/Reward Ratings Methodology
93
Ratings Overview
94
Table: Pharmaceutical Risk/Reward Ratings Indicators
94
Indicator Weightings
95

The Lithuania Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Lithuania Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Lithuania pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Lithuania, to test other views - a key input for successful budgeting and strategic business planning in the Lithuanian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Lithuanian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Lithuania.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc